• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Pfizer again?


<















Nope!

PFE is not interested in AGN. That ship has sailed people.

Why not? They can get the Botox franchise, which is what they’ve wanted all along, at a fraction of the cost they were going to pay 2 years ago. They can sell off or discontinue everything else, making the deal more attractive. Sanders won’t get his nearly 1/2 Billion dollar pay day like he would have but at this point it’s better than nothing
 




Why not? They can get the Botox franchise, which is what they’ve wanted all along, at a fraction of the cost they were going to pay 2 years ago. They can sell off or discontinue everything else, making the deal more attractive. Sanders won’t get his nearly 1/2 Billion dollar pay day like he would have but at this point it’s better than nothing

They wanted the tax domicile, period. the first year tax savings alone were worth 10x any product revenues. Now that the corporate tax reform is in place the tax savings in the original deal just aren’t there.
 




They wanted the tax domicile, period. the first year tax savings alone were worth 10x any product revenues. Now that the corporate tax reform is in place the tax savings in the original deal just aren’t there.





Not only that, but PFE is not going to take a gamble on a pipeline that has only 2 potential drugs which have a 50-75% chance of approval even with good safety studies. Botox is worth lots but they are not interested in just that.